These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 9193132)

  • 21. Synthesis and biological evaluation of a new series of phenylhydroquinone derivatives as inhibitors of EGF-R-associated PTK activity.
    Million ME; Mailliett P; Chen H; Bashiardes G; Boiziau J; Parker F; Commerçon A; Tocque B; Roques BP; Garbay C
    Anticancer Drug Des; 1996 Mar; 11(2):129-53. PubMed ID: 8630186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.
    Uckun FM; Narla RK; Jun X; Zeren T; Venkatachalam T; Waddick KG; Rostostev A; Myers DE
    Clin Cancer Res; 1998 Apr; 4(4):901-12. PubMed ID: 9563884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide.
    Dinney CP; Parker C; Dong Z; Fan D; Eve BY; Bucana C; Radinsky R
    Clin Cancer Res; 1997 Feb; 3(2):161-8. PubMed ID: 9815668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
    Rudrabhatla P; Rajasekharan R
    Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tannic acid, a potent inhibitor of epidermal growth factor receptor tyrosine kinase.
    Yang EB; Wei L; Zhang K; Chen YZ; Chen WN
    J Biochem; 2006 Mar; 139(3):495-502. PubMed ID: 16567414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor.
    Yang EB; Zhao YN; Zhang K; Mack P
    Biochem Biophys Res Commun; 1999 Jul; 260(3):682-5. PubMed ID: 10403826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sporostatin, a novel and specific inhibitor of EGF receptor kinase.
    Murakami Y; Ishii A; Mizuno S; Yaginuma S; Uehara Y
    Anticancer Res; 1999; 19(5B):4145-9. PubMed ID: 10628366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Fay JR; Steele VE; Lubet RA; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):657-66. PubMed ID: 8824370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
    Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.
    Geissler JF; Roesel JL; Meyer T; Trinks UP; Traxler P; Lydon NB
    Cancer Res; 1992 Aug; 52(16):4492-8. PubMed ID: 1643641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.
    Sion-Vardy N; Vardy D; Rodeck U; Kari C; Levin RM; Malkowicz SB
    J Surg Res; 1995 Dec; 59(6):675-80. PubMed ID: 8538164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.
    Alfaro-Lopez J; Yuan W; Phan BC; Kamath J; Lou Q; Lam KS; Hruby VJ
    J Med Chem; 1998 Jun; 41(13):2252-60. PubMed ID: 9632358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity.
    Gulli LF; Palmer KC; Chen YQ; Reddy KB
    Cell Growth Differ; 1996 Feb; 7(2):173-8. PubMed ID: 8822200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors.
    Brunton VG; Kelland LR; Lear MJ; Montgomery GJ; Robertson JH; Robins DJ; Queen J; Workman P
    Anticancer Drug Des; 1996 Jun; 11(4):265-95. PubMed ID: 8679052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
    Brunton VG; Carlin S; Workman P
    Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of a series of hydroxybenzylphenylamine derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
    Chen H; Bashiardes G; Mailliet P; Commercon A; Sounigo F; Boiziau J; Parker F; Tocque B; Roques BP; Garbay C
    Anticancer Drug Des; 1996 Jan; 11(1):49-71. PubMed ID: 8639248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.